Literature DB >> 29315976

Therapeutic role of rifampicin in Alzheimer's disease.

Burak Yulug1,2, Lütfü Hanoglu1,2, Mehmet Ozansoy2,3, Dogan Isık4, Ulkan Kilic5, Ertugrul Kilic2,3, Wolf Rüdiger Schabitz6.   

Abstract

Rifampicin exerts significant brain protective functions in multiple experimental models. Here we summarize the underlying mechanisms of the neuroprotective and pro-cognitive effects of rifampicin that are mediated by its anti-inflammatory, anti-tau, anti-amyloid, and cholinergic effects. Beyond suggesting that rifampicin shows strong brain protective effects in preclinical models of Alzheimer's disease, we also provide substantial clinical evidence for the neuroprotective and pro-cognitive effects of rifampicin. Future neuroimaging studies combined with clinical assessment scores are the following steps to be taken in this field of research.
© 2018 The Authors. Psychiatry and Clinical Neurosciences © 2018 Japanese Society of Psychiatry and Neurology.

Entities:  

Keywords:  Alzheimer's disease; amyloid beta clearance; neuroprotection; oligomeric amyloid hypothesis; rifampicin

Mesh：

Substances：

Year:  2018        PMID： 29315976     DOI： 10.1111/pcn.12637

Source DB:  PubMed          Journal:  Psychiatry Clin Neurosci        ISSN： 1323-1316            Impact factor:   5.188


  13 in total

Review 1.  Gauging the role and impact of drug interactions and repurposing in neurodegenerative disorders.

Authors:  Dharmendra Kumar Khatri; Amey Kadbhane; Monica Patel; Shweta Nene; Srividya Atmakuri; Saurabh Srivastava; Shashi Bala Singh
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-04-08

Review 2.  Challenges of repurposing tetracyclines for the treatment of Alzheimer's and Parkinson's disease.

Authors:  Iva Markulin; Marija Matasin; Viktorija Erdeljic Turk; Melita Salković-Petrisic
Journal:  J Neural Transm (Vienna)       Date:  2022-01-04       Impact factor: 3.850

Review 3.  The Use of Antimicrobial and Antiviral Drugs in Alzheimer's Disease.

Authors:  Umar H Iqbal; Emma Zeng; Giulio M Pasinetti
Journal:  Int J Mol Sci       Date:  2020-07-12       Impact factor: 5.923

4.  Treating psychiatric symptoms and disorders with non-psychotropic medications
.

Authors:  Vincent Hede; Cédric Devillé
Journal:  Dialogues Clin Neurosci       Date:  2019       Impact factor: 5.986

Review 5.  Gut-Brain Axis: Role of Gut Microbiota on Neurological Disorders and How Probiotics/Prebiotics Beneficially Modulate Microbial and Immune Pathways to Improve Brain Functions.

Authors:  Kanmani Suganya; Byung-Soo Koo
Journal:  Int J Mol Sci       Date:  2020-10-13       Impact factor: 5.923

6.  PICALM mRNA Expression in the Blood of Patients with Neurodegenerative Diseases and Geriatric Depression.

Authors:  Hiroshi Kumon; Yuta Yoshino; Yu Funahashi; Hiroaki Mori; Mariko Ueno; Yuki Ozaki; Kiyohiro Yamazaki; Shinichiro Ochi; Takaaki Mori; Jun-Ichi Iga; Masahiro Nagai; Masahiro Nomoto; Shu-Ichi Ueno
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

Review 7.  Repurposing Licensed Drugs for Use Against Alzheimer's Disease.

Authors:  Leslie C Norins
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

8.  Identifying Blood Transcriptome Biomarkers of Alzheimer's Disease Using Transgenic Mice.

Authors:  Shinichiro Ochi; Jun-Ichi Iga; Yu Funahashi; Yuta Yoshino; Kiyohiro Yamazaki; Hiroshi Kumon; Hiroaki Mori; Yuki Ozaki; Takaaki Mori; Shu-Ichi Ueno
Journal:  Mol Neurobiol       Date:  2020-08-20       Impact factor: 5.590

Review 9.  Marine Natural Products, Multitarget Therapy and Repurposed Agents in Alzheimer's Disease.

Authors:  Márcia Martins; Renata Silva; Madalena M M Pinto; Emília Sousa
Journal:  Pharmaceuticals (Basel)       Date:  2020-09-11

Review 10.  Antibiotics and the Nervous System-Which Face of Antibiotic Therapy Is Real, Dr. Jekyll (Neurotoxicity) or Mr. Hyde (Neuroprotection)?

Authors:  Magdalena Hurkacz; Lukasz Dobrek; Anna Wiela-Hojeńska
Journal:  Molecules       Date:  2021-12-09       Impact factor: 4.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.